•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objective The aim of this study was to assess serum testosterone in patients with chronic obstructive pulmonary disease (COPD) and discuss the impacts of decreased serum testosterone levels as an anabolic hormone. Background Decreased levels of anabolic hormone may occur in COPD patients; thus, both serum testosterone and luteinizing hormone levels should be investigated. Participants and methods This case–control study was carried out in El-Mahalla Chest Hospital from October 2015 to February 2016. A total of 55 individuals were enrolled in the study: 35 adult male COPD patients and 20 age-matched men as a control group. All participants were subjected to a detailed assessment of history, clinical examination, chest radiography, O2saturation, spirometry [measurement of forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC), FVC, FEV1% of predicted], complete blood picture, liver function tests, kidney function tests, and random blood sugar; also, both serum testosterone and luteinizing hormone levels were measured using direct chemiluminescent technology. Results The smoking index of the COPD patients was 66.06 ± 6.83 pack-years and that of the control group was 11.25 ± 1.86 pack-years, with a highly statistically significant difference between both groups (P < 0.001). Oxygen saturation of COPD patients was 92.51 ± 1.77% and that of the control group was 96.45 ± 0.69%, with a highly statistically significant difference between the two groups (P < 0.001). In terms of the FEV1/FVC ratio, FEV1% and FVC% were highly statistically significantly lower in COPD patients compared with the control participants (P > 0.001). Testosterone was highly statistically significantly lower in COPD patients compared with the control group (P > 0.001). Conclusion Disturbances in serum testosterone hormone levels in COPD patients were correlated with smoking, FEV1, and hypoxemia.

Download

Share

COinS